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Hutchinson-Gilford Progeria Syndrome:
Pathophysiology and Possible Treatments
Pearl Hersh
Abstract
Named after the two scientist who independently described the condition, Hutchinson-Gilford Progeria Syndrome
(HGPS) occurs due to a mutation in the LMNA gene that codes for Lamin A, a filament protein that acts to form the nuclear lamina in the cell nucleus. This mutation is a single C-to-T substitution at nucleotide 1824 of the LMNA gene. As a
result of this mutation, an abnormal protein named 'progerin' is synthesized instead of Lamin A, causing the nuclear
membrane to be malformed. Since protein farnesylation is needed to target progerin to the nuclear rim, farnesyltransferase inhibitor has been proposed as a form of treatment that could reduce the occurrence of misshapen nuclei and
alleviate HGPS symptoms.

Introduction
Aging is a process that’s inevitable. Over a typical
lifespan, the body loses its ability to maintain homeostasis
and fight off disease. The elderly also experience atherosclerosis that can lead to strokes and myocardial infarctions. Arthritic joint pain and stiffness are also common, as
is thinning of the skin. Researches have speculated about
the precise physical changes in the body that manifest
themselves as the process of aging (Burtner and Kennedy
2010).
The answer may lie in a very rare segment of the population who suffer from progeriod syndromes that cause accelerated aging. The most severe of this group is Progeria,
which causes rapid aging in children and death by adolescence. The calculated mean lifespan in Progeria patients is
only 13 years of age (Kudlow et al. 2007).

HGPS Pathophysiology
Hutchinson-Gilford Progeria Syndrome (HGPS) is
caused by a de novo heterozygous point mutation, changing a GGC sequence to GGT in exon 11 of the LMNA gene.
This mutation causes a 50 amino acid sequence deletion at
the carboxyl terminus of prelamin A, producing a truncated progerin in the place of Lamin A (Neelam et al. 2012).
Lamins are intermediate filament proteins that polymerize
to form nuclear lamina, a meshwork forming the inner nuclear membrane. Lamin A belongs to the A-type lamins
that includes Lamin A and Lamin C. Lamin C differs very

slightly from Lamin A by its C-terminal extension, which
has 90 less residues than Lamin A. Both Lamin A and C contribute to the shaping of the nuclear membrane. When
progerin is present in place of Lamin A, the nuclear membrane takes on an abnormal morphology (Rakha, et al.
2011).
The Proteins of the nuclear lamina were once thought to
play merely a structural role. Through studying diseases
that affect these proteins, it has become apparent that
they also play an important role in various cellular functions such as signal transduction and gene expression
(Scaffidi and Misteli, 2006). Therefore, mutations affecting
these proteins can have devastating effects on multiple
organ systems in the body, as in the case of HutchinsonGilford Progeria Syndrome (HGPS).
HGPS is part of a group of rare diseases known as
laminopathies, in which the proteins of the nuclear lamina
are affected. These diseases all result from LMNA gene
mutations and include lipodystrophy, muscular dystrophy,
peripheral neuropathy and Progeria (Liu, et al. 2010). In
lipodystrophy, symptoms begin at the onset of puberty
and patients experience loss of subcutaneous fat, high cholesterol and type-II diabetes. Muscular dystrophy is similar
in that symptoms appear close to puberty and cause progressive muscle wasting. Peripheral Neuropathy is a laminopathy that causes nerve dysfunction. Progeria is perhaps
the most devastating of them all since symptom onset begins at a few months of age and death from cardiovascular
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illness is likely by age 13.

deformities caused speech and swallowing difficulties and
hearing loss. When measured at age 8, she fell below the
HGPS Phenotypes
3rd percentile in both height and weight compared to othHGPS disease symptoms include; slow growth, scleroder- er her age and she remained very thin and small in stature
matous changes of the skin, alopecia, osteoporosis and (Ibid).
atherosclerotic vascular disease. (Yang, et al. 2006) These
Diagnoses came later for an Indian boy who
symptoms contribute to a very distinctive look common to
showed up at a Dermatology clinic at age 4. He had loss of
all Progeria patients. They are sometimes described as aphair, including eyelashes and eyebrows since age 1, and
pearing like ‘little aliens’ due to their diminutive stature,
stunted growth. Doctors noticed his distinct prominent
lack of hair, and small heads with prominent noses.
veins and eyes, beaked nose and high-pitched voice. His
problems were far from merely dermatological, and he
Figure 1: Face of a Progeria patient showing alopecia, loss
was diagnosed with Progeria after confirmatory imaging
of eyebrow and eyelashes and prominent eyes with a tastudies (Agarwal, et al. 2010)
pered nasal tip. (Agarwal, et al. 2010)

Vertebrate Progeriod Models
Researchers attempting to better understand and
treat Progeria, need models to work with. The incidence of
Progeria is so infrequent in the population due to the rarity
of the specific LMNA mutation that causes it. Nearly all
Progeria patients in the world today are well known and
have participated in studies by contributing medical data
and samples. In the century or so since the discovery of the
syndrome, only about 100 cases have been documented
(Mohamed and Jayachandran 2009) and today, with only
48 known patients whose lifespans are short, these samples are severely limited.
Human Progeria research subjects are not only
limited in number, it often isn’t safe for them to participate
in early stages of drug trials. Before a drugs potency can be
determined, use in humans is unethical. Thus, creating animal models to test Progeria drugs is an important key to
ultimately finding a cure.

In one particular Chinese girl with Progeria, HGPS
diagnosis was made at 2 months of age. The child was the
second-born of healthy parents with no remarkable family
medical history. The first symptom that raised concern was
a loss of subcutaneous fat in her abdomen and buttocks,
where a baby would normally exhibit plumpness. Her hair
After much trial and error, mice have been sucwas also unusually sparse and her veins were noticeably
cessfully genetically modified to be ZMPSTE24 deficient,
prominent for 2 months of age (Chen, et al. 2012).
causing the expression of Progeria-like symptoms (Osorio,
At 2 years of age, the child had already lost all of et al. 2009). ZMPSTE24 is an enzyme that completes the
her hair and was beginning to develop a characteristic Pro- post-translational processing of Pre-lamin A by cleaving it
geria face. Her forehead jutted out, her eyes were promi- into its mature form of lamin A (Liu, et al. 2010). Without
nent and her jaw was undersized. Imaging studies taken the ZMPSTE24 enzyme, Pre-lamin A processing is halted
over ages 4 and 5, showed patterns of bone resorption in and this results in a truncated Lamin A protein similar to
her clavicles and distal phalanges along with hip displace- the progerin protein found in patients with HGPS.
ment and dental crowding (Ibid).
Zebrafish models expressing truncated Lamin A
The symptoms progressed rapidly and by age 6 the
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proteins have also been genetically engineered and studied. Using a splice-block method to delete the 8 amino-acid
site of pre-lamin A cleavage in zebrafish embryos, researchers created progeriod zebrafish models. These
zebrafish then exhibited accelerated aging and shortened
lifespans along with other symptoms such as cell-cycle arrest and cartilage defects that appeared as craniofacial
abnormalities (Koshimizu, et al. 2011).

ies, hence the acronym ‘CaaX Protein’. In Prelamin A, the
CaaX terminal is made of cysteine, alipathic serine and isoleucine, and methionine (CSIM) (Dominici, et al. 2009).
In the first processing step of polyisoprenylation,
farynesyltransferase recognizes methionine and adds a 15
carbon farnesyl to the CSIM sequence. Proteolysis is next,
in which endoprotease ZMPSTE24 removes the ‘SIM’ portion of the CSIM sequence (Dominici, et al. 2009). In the
final prenylation step, carboxyl methylation of the farnesylated prelamin A occurs via methyltransferase to produce
carboxymethylated-farnesylated prelamin A (preLAfarnesyl-C-H3).

Both the ZMPSTE24 deficient mice and the
progeriod zebrafish models were genetically altered in a
way where Lamin A was not able to be processed into its
mature form. Another mouse model however, was modified so that it would not produce the Lamin A protein at all.
This lamin A deficient mouse would only produce Lamin C,
a similar Lamin protein normally produced alongside Lamin
A. The Lamin C-only mice had no tissue abnormalities and
appeared non-diseased (Fong et. al 2006).

Figure 2: Prenylation process of the CAAX proteins. The protein prenylation process includes 3 steps: polyisoprenylation,
proteolysis, and carboxyl methylation. Polyisoprenylation is the
attachment of an isoprenoid lipid by protein farnesyltransferase (FTase) or geranylgeranytransferase type I (GGTase-I) to
CAAX box. In the second step, the CAAX residues are proteolysed by prenyl protein peptidase RCE1 family to release AAX. This is followed by subsequent endoproteolytic trimming
and carboxyl methylation significantly increases the hydropho-

In a state of complete lack of Lamin A, Lamin C
seems to compensate and therefore, no pathologies result.
It seems that the truncated, pre-lamin or progerin form of
the Lamin A that accumulates when the protein’s processing is halted, is the cause of the diseased cell (Fong et.
al 2006). This realization can help researchers treat laminopathic diseases by developing drugs that can prevent immature lamin proteins from doing harm and possibly trigger the non-affected Lamin types (unaffected Lamin C in
Progeria patients) to compensate for the missing protein.

FTI Treatment
The advantage of farnesyltransferase inhibitor (FTI)
is that it can mask HGPS symptoms even while the abnormal Progerin protein is still being expressed. By preventing
progerin from attaching to the nuclear rim, FTI can increase the amount of normal-shaped nuclei (Capell, et al.
2005).
Progerin, a truncated form of pre-lamin A, is missing the ZMPSTE24 cleavage site and will therefore retain
the cysteine C-terminal that is farnesylated and carboxymethylated (Liu, et al. 2010). The retention of the toxic
farnesyl group will cause progerin to incorporate itself into
the nuclear envelope in an abnormal fashion. Once in the
nuclear envelope, progerin will produce an abnormal heterochromatin assembly and lead to an increase in DNA

Prelamin A requires a 3-step prenylation processing to be converted into mature Lamin A. The prenylation occurs rapidly and unprocessed Prelamin A is barely
detectable (Gao, et al. 2009). A similar form of posttranslational modification occurs in all CaaX proteins. This
category of proteins contains a specific amino acid sequence at the c-terminal consisting of a cysteine residue, 2
alipathic residues and another c-terminal acid ‘x’ that var62
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damage (Zaremba-Czogalla et al. 2011). Structurally, the
nuclear membrane will also become misshapen and stiff.
This characteristic is known as nuclear blebbing and is a
distinct phenotype of progeria.

form of treatment. Since Lamin A expression is developmentally regulated, it isn’t present in embryonic cells and
stem cells (Mounkes et al. 2003). This can be seen in the
normal appearance of Progeria-modeling mouse embryos
and progeria patients up until a few months of age, when
progerin starts to proliferate in cells in place of Lamin A.
Stem cell use has been explored as a means of initiating
tissue regeneration and offsetting the accelerated rate of
cell aptosis that causes rapid aging in Progeria patients
(Halaschek-Wiener and Brooks-Wilson 2007).

Lonafarnib, a farnesyltransferase inhibitor drug
initially used for cancer treatment, has recently been tested on patients with HGPS in a clinical trial. In 2007, 25 progeria patients from 16 countries around the world came to
Boston, Massachusetts over a period of 2 years to receive
Lonafarnib. They were measured for changes in weight,
skeletal rigidity, hearing and cardiovascular health. The
study showed that the children improved in at least one or
more of the measured areas over the course of the trial.
Most importantly, in the essential area of cardiovascular
health, which is the cause of death in progeria patients, all
but one participant showed improvement (Gordon, et al.
2012)

Conclusion
Progeria is a rare, devastating and terminal disease
caused by a single gene mutation. Since the mutation is
located on the LMNA gene, the Nuclear Lamina Proteins
are affected. A single nucleotide substitution causes a 50
base pair deletion of pre-lamin A (Lain A pre-cursor). Lamin
A is then prevented from completing its processing and
remains in an immature form called progerin. The accumulation of progerin has a multi-systemic effect leading to
rapid aging and early death from complications of atherosclerosis. Lonafarnib, a FTI inhibitor, has been proposed as
a form of treatment and recent studies have shown it is
effective in alleviating some of the symptoms of Progeria.

Other Treatments
In the presence of farnesyltranferase inhibitors,
the cell will often adapt and turn to other processing pathways such as grenygrenylation (Gordon et al. 2008). In
place of polyisoprenylation (addition of a 15-carbon farnesyl) via farnesyltransferase, a similar enzyme, geranylgeranyltransferase I (GGTase I) can add a 20-carbon
geranylgeranyl group to the Pre-lamin A (Sousa et al.
2008). This adaptation mechanism can lessen the effectiveness of FTI treatment. A combination of statins and aminobisphosphonates, combined with FTI treatment can inhibit
both farnesylation and grenygrenylation pathways.
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